Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response to sunitinib in medullary thyroid cancer.

× No keyword cloud information.

6 in total

Review 1. Management of hereditary medullary thyroid carcinoma.

Authors: Theodora Pappa; Maria Alevizaki
Journal: Endocrine Date: 2016-02-02 Impact factor: 3.633

2. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Authors: David S Hong; Maria E Cabanillas; Jennifer Wheler; Aung Naing; Apostolia M Tsimberidou; Lei Ye; Naifa L Busaidy; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Alder K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Razelle Kurzrock
Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958

Review 3. Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.

Authors: Ph Kaldrymides; I Kostoglou-Athanassiou; A Gkountouvas; E Veniou; N Ziras
Journal: Endocrine Date: 2010-01-06 Impact factor: 3.633

Review 4. Activated RET and ROS: two new driver mutations in lung adenocarcinoma.

Authors: Marc Bos; Masyar Gardizi; Hans-Ulrich Schildhaus; Reinhard Buettner; Juergen Wolf
Journal: Transl Lung Cancer Res Date: 2013-04

Review 5. Medical management of metastatic medullary thyroid cancer.

Authors: Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal: Cancer Date: 2014-06-18 Impact factor: 6.860

6. Advanced medullary thyroid cancer: pathophysiology and management.

Authors: Carla Vaz Ferreira; Débora Rodrigues Siqueira; Lucieli Ceolin; Ana Luiza Maia
Journal: Cancer Manag Res Date: 2013-05-08 Impact factor: 3.989

6 in total